Grow City CZ founder Michal Otipka has spent nearly 30 years building Europe’s most influential grow shop. From police raids to legalization, discover how his Prague-based “permanent exhibition” is reshaping home cultivation across the continent.
Congress’s 2025 spending bill includes a sweeping change to federal hemp law, redefining legal hemp and effectively banning most hemp-derived THC products. Industry leaders warn the move could “wipe out” 95% of the market, while advocates say it underscores the need for unified cannabis regulation.
Tobacco giants are investing heavily in cannabis, from R&D partnerships to vapor technology and wellness products. As integration accelerates, the focus shifts from resistance to direction—how to merge corporate infrastructure with the plant’s creative and cultural foundations.
Germany’s Cannabis Act evaluation shows fewer youth consumers, no rise in accidents, and declining crime. Bloomwell CEO Niklas Kouparanis warns against restricting medical access, arguing it would re-criminalize patients and undermine public health progress.
How will cannabis advertising change if the plant moves to Schedule III? From 280E relief to FDA oversight, discover what rescheduling means for marketing, media access, and how culture-driven brands can stay ahead.
President Donald Trump is expected to announce “Make Cannabis Great Again,” rescheduling cannabis to Schedule III. The move would legalize medical use across the U.S., spark global reforms, and trigger a worldwide race in cannabis research and development.
With Trump open to cannabis rescheduling and the DEA making it a priority, industry leaders see a historic shift ahead. Schedule III could ease taxes, boost research, and spur growth—but experts warn it’s only the first step toward real federal reform.
A new book by Darren Gleeman, The Cannabis ESOP Architect, reveals the only IRS-approved way for cannabis founders to sell their business tax-free, preserve culture, and permanently eliminate the burden of IRC 280E through Employee Stock Ownership Plans.
The Flowery has been named No. 86 on the 2025 Inc. 5000 list of America’s Fastest-Growing Private Companies. With 3,800% revenue growth over three years, the multi-state brand continues to expand while staying true to its culture-first mission.
New York’s OCM has flagged 152 cannabis retailers and applicants for violating school proximity laws. Affected businesses must relocate or risk losing licensure as the state races to correct past regulatory errors.
From California to Portugal and Thailand, global cannabis raids reveal a persistent and dangerous illicit market—fueled by poor regulation, political inaction, and unsustainable taxation. Can lawmakers finally learn from the chaos and build systems that protect both people and the plant?
At New York’s latest Cannabis Control Board meeting, applicants learned they may wait until 2033 for license approval—fueling outrage as new marketing rules roll out and thousands remain stuck in regulatory limbo.
Thailand's cannabis U-turn has upended an entire industry. As new laws push the plant into strict medical control, small businesses and farmers struggle—while clinics and corporate growers gain ground. What does this mean for the future of cannabis in Asia?
Thailand’s $1.2B cannabis market is reeling as 90% of dispensaries are shut down and the government moves to reclassify the plant as a narcotic. Some say it’s chaos—others call it a necessary reset.
A new Bloomwell survey reveals 42% of German cannabis patients would return to illicit sources if digital access is restricted. With patient numbers up 1100% since reclassification, leaders warn that political rollbacks could reverse medical progress.
